Obesity and cancer risk: Evidence, mechanisms, and recommendations

Annals of the New York Academy of Sciences

Volumn 1271, Issue 1, 2012, Pages 37-43

  Vucenik, Ivana ^a   Stains, Joseph P ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer; Mechanisms; Obesity; Prevention; Recommendations

Indexed keywords

ADIPONECTIN; CYTOKINE; GROWTH FACTOR; INOSITOL POLYPHOSPHATE; INSULIN; LEPTIN; PROTEIN KINASE B; SOMATOMEDIN C;

ARTICLE; BODY FAT; BODY WEIGHT; BREAST CANCER; CALORIC RESTRICTION; CANCER GROWTH; CANCER INCIDENCE; CANCER MORTALITY; CANCER PREVENTION; CANCER RISK; CANCER SURVIVAL; CARCINOGENESIS; CELL PROLIFERATION; COLON CANCER; DISEASE ASSOCIATION; ENDOMETRIUM CANCER; ENERGY BALANCE; ENERGY METABOLISM; ESOPHAGUS CANCER; GALLBLADDER CANCER; HEMATOLOGIC MALIGNANCY; HUMAN; IMMOBILIZATION; INFLAMMATION; KIDNEY CANCER; LIVER CANCER; OBESITY; PANCREAS CANCER; PHYSICAL ACTIVITY; SYSTEMATIC REVIEW (TOPIC);

EID: 84867344530     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2012.06750.x     Document Type: Article

References (61)

1. World Cancer Research Fund/American Institute for Cancer Research. 2007. Food, Nutrition, Physical Activity, and the Prevention of Cancer: A Global Perspective. AICR. Washington, DC.
2. Centers for Disease Control and Prevention, Overweight and Obesity; Defining Overweight and Obesity. Available at: http://www.cdc.gov/obesity/defining.html [Accessed May, 2012].
3. Karnik, S.D. & A. Kanekar. 2012. Childhood obesity: a global public health crisis. Int. J. Prev. Med. 3: 1-3.
4. Flegal, K.M., M.D. Carroll, B.K. Kit & C.L. Ogden. 2012. Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999-2010. J. Am. Med. Assoc. 307: 491-497.
5. Ogden, C.L, M.D. Carroll, B.K. Kit & K.M. Flegal. 2012. Prevalence of obesity and trends in body mass index among US children and adolescents, 1999-2010. J. Am. Med. Assoc. 307: 483-490.
6. Jemal, A., F. Bray, M.M. Center, et al. 2011. Global cancer statistics. CA Cancer J. Clin. 61: 69-90.
7. Siegel, R., D. Naishadham & A. Jemal. 2012. Cancer statistics, 2012. CA Cancer J. Clin. 62: 10-29.
8. Altekruse, S., C. Kosary, M. Krapcho, et al. 2010. SEER Cancer Statistics Review, 1975-2008. National Cancer Institute. Bethesda, MD. Available at: http://seer.cancer.gov/csr/1975_2007/ [Accessed August 2012].
9. Rossen, L.M. & E.A. Rossen. 2012. Obesity 101. Springer Publishing Co., LLC. New York.
10. Berrington de Gonzalez, A., P. Hartge, J.R. Cerhan, et al. 2010. Body-mass index and mortality among 1.46 million white adults. N. Engl. J. Med. 363: 2211-2219.
11. Lichtman, M.A. 2010. Obesity and the risk for a hematological malignancy: leukemia, lymphoma, or myeloma. Oncologist 15: 1083-1101.
12. Kaidar-Person, O., G. Bar-Sela & B. Person. 2011. The two major epidemics of the twenty-first century: obesity and cancer. Obes. Surg. 21: 1792-1797.
13. Parekh, N., U. Chandran & E.V. Bandera. 2012. Obesity in cancer survival. Annu. Rev. Nutr. 32: 311-342.
14. Calle, E.E., C. Rodriguez, K. Walker-Thurmond & M.J. Thun. 2003. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N. Engl. J. Med. 348: 1625-1638.
15. Calle, E.E. & R. Kaaks. 2004. Overweight, obesity and cancer: epidemiological evidence and mechanisms. Nat. Rev. Cancer 4: 579-591.
16. Drew, J.E. 2012. Molecular mechanisms linking adipokines to obesity-related colon cancer: focus on leptin. Proc. Nutr. Soc. 71: 175-180.
17. Dalamaga, M., K.N. Diakopoulos & C.S. Mantzoros. 2012. The role of adiponectin in cancer: a review of current evidence. Endocr. Rev. 33: 547-594.
18. Gallagher, E.J. & D. LeRoith. 2011. Minireview: IGF, insulin, and cancer. Endocrinology 152: 2546-2551.
19. Hursting, S.D. & N.A. Berger. 2010. Energy balance, host-related factors, and cancer. J. Clin. Oncology 28: 4058-4065.
20. Chen, J. 2011. Multiple signal pathways in obesity-associated cancer. Obes. Rev. 12: 1063-1070.
21. Harvey, A.E., L.M. Lashinger & S.D. Hursting. 2011. The growing challenge of obesity and cancer: an inflammatory issue. Ann. N.Y. Acad. Sci. 1229: 45-52.
22. Kershaw, E.E. & J.S. Flier. 2004. Adipose tissue as an endocrine organ. J. Clin. Endocrinol. Metab. 89: 2548-2556.
23. Gao, J., J. Tian, Y. Lv, et al. 2009. Leptin induces functional activation of cyclooxygenase-2 through JAK2/STAT3, MAPK/ERK, and PI3K/AKT pathways in human endometrial cancer cells. Cancer Sci. 100: 389-395.
24. Jaffe, T. & B. Schwartz. 2008. Leptin promotes motility and invasiveness in human colon cancer cells by activating multiple signal-transduction pathways. Int. J. Cancer 123: 2543-2556.
25. Hursting, S.D., L.M. Lashinger, K.W. Wheatley, et al. 2008. Reducing the weight of cancer: mechanistic targets for breaking the obesity-carcinogenesis link. Best. Pract. Res. Endocrinol. Metab. 22: 659-669.
26. Kaaks, R., A. Lukanova & M.S. Kurzer. 2002. Obesity, endogenous hormones, and endometrial cancer risk: a synthetic review. Cancer Epidemiol. Biomarkers Prev. 11: 1531-1543.
27. Taubes, R. 2012. Cancer research. Unraveling the obesity-cancer connection. Science 335: 28, 30-32.
28. Dowling, R.J., S. Niraula, V. Stambolic & P.J. Goodwin. 2012. Metformin in cancer: translational challenges. J. Mol. Endocrinol. 48: R31-R43.
29. Hursting, S.D., S.M. Smith, L.M. Lashinger, et al. 2010. Calories and carcinogenesis: lessons learned from 30 years of calorie restriction research. Carcinogenesis 31: 83-89.
30. Zhu, Z., W. Jiang, J. McGinley, et al. 2005. Effects of dietary energy repletion and IGF-1 infusion on the inhibition of mammary carcinogenesis by dietary energy restriction. Mol. Carcinog. 42: 170-176.
31. Hursting, S.D., B.R. Switzer, J.E. French & F.W. Kari. 1993. The growth hormone: insulin-like growth factor 1 axis is a mediator of diet restriction-induced inhibition of mononuclear cell leukemia in Fisher rats. Cancer Res. 53: 2750-2757.
32. Dunn, S.E., F.W. Kari, J. French, et al. 1997. Dietary restriction reduces insulin-like growth factor I levels, which modulates apoptosis, cell proliferation, and tumor progression in p53-deficient mice. Cancer Res. 57: 4667-4672.
33. Renehan, A.G., J. Frystyk & A. Flyvbjerg. 2006. Obesity and cancer risk: the role of the insulin-IGF axis. Trends Endocrinol. Metab. 17: 328-336.
34. Liu, P., H. Cheng, T.M. Roberts & J.J. Zhao. 2009. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat. Rev. Drug Discov. 8: 627-644.
35. Kalaany, N.Y. & D.M. Sabatini. 2009. Tumours with PI3K activation are resistant to dietary restriction. Nature 458: 725-731.
36. Moore, T., L. Beltran, S. Carbajal, et al. 2008. Dietary energy balance modulates signaling through the Akt/Mammalian Target of Rapamycin pathways in multiple epithelial tissues. Cancer Prev. Res. 1: 65-76.
37. Woods, S.C., R.J. Seeley, D. Porte, Jr., et al. 1998. Signals that regulate food intake and energy homeostasis. Science 280: 1378-1383.
38. Dann, S.G., A. Selvaraj & G. Thomas. 2008. mTOR Complex1-S6K1 signaling: at the crossroads of obesity, diabetes and cancer. Trends Mol. Med. 13: 252-259.
39. Jiang, W., Z. Zhu & H.J. Thompson. 2008. Dietary energy restriction modulates the activity of Akt and mTOR in mammary carcinomas, mammary gland, and liver. Cancer Res. 68: 5492-5499.
40. Fierz, Y., R. Novosyadlyy, A. Vijayakumar, et al. 2010. Mammalian target of rapamycin inhibition abrogates insulin-mediated mammary tumor progression in type 2 diabetes. Endocr. Relat. Cancer 17: 941-951.
41. Novosyadlyy, R., D.E. Lann, A. Vijayakumar, et al. 2010. Insulin-mediated acceleration of breast cancer development and progression in a nonobese model of type 2 diabetes. Cancer Res. 70: 741-751.
42. Moore, T., S. Carbajal, L. Beltran, et al. 2008. Reduced susceptibility to two-stage skin carcinogenesis in mice with low circulating insulin-like growth factor I level. Cancer Res. 68: 3680-3688.
43. Olivo-Marston, S.E., S.D. Hursting, J. Lavigne, et al. 2009. Genetic reduction of circulating insulin-like growth factor-1 inhibits azoxymethane-induced colon tumorigenesis in mice. Mol. Carcinog. 48: 1071-1076.
44. Chakraborty, A., S. Kim & S.H. Snyder. 2011. Inositol pyrophosphates as mammalian cell signals. Sci. Signal. 4: 188: re1.
45. Chakraborty, A., M.A. Koldobskiy, N.T. Bello, et al. 2010. Inositol pyrophosphates inhibit Akt signaling, thereby regulating insulin sensitivity and weight gain. Cell 143: 897-910.
46. Shames, D.S. & J.D. Mina. 2008. IP6K2 is a client for HSP90 and a target for cancer therapeutics development. Proc. Natl. Acad. Sci. U. S. A. 105: 1389-1390.
47. Aoki, M., V. Sobek, D.J. Maslyar, et al. 2002. Oncogenic transformation by beta-catenin: deletion analysis and characterization of selected target genes. Oncogene 10: 6983-6991.
48. Chakraborty, A., M.A. Koldobskiy, K.M. Sixt, et al. 2008. HSP90 regulates cell survival via inositol hexakisphosphate kinase-2. Proc. Natl. Acad. Sci. U. S. A. 105: 1134-1139.
49. Koldobskiy, M.A., A. Chakraborty, J.K. Werner, Jr., et al. 2010. p53-mediated apoptosis requires inositol hexakisphosphate kinase-2. Proc. Natl. Acad. Sci. U. S. A. 107: 20947-20951.
50. Chakraborty, A., J.K. Werner, Jr., M.A. Koldobskiy, et al. 2011. Casein kinase-2 mediates cell survival through phosphorylation and degradation of inositol hexakisphosphate kinase-2. Proc. Natl. Acad. Sci. U. S. A. 108: 2205-2209.
51. Morrison, B.H., R. Haney, E. Lamarre, et al. 2009. Gene deletion of inositol hexakisphosphate kinase 2 predisposes to aerodigestive tract carcinoma. Oncogene 28: 2383-2392.
52. Morrison, B.H, J.A. Bauer, J. Hu, et al. 2002. Inositol hexakisphosphate kinase 2 sensitizes ovarian carcinoma celle to multiple cancer therapeutics. Oncogene 21: 1882-1889.
53. Morrison, B.H., J.A. Bauer, D.V. Kalvakolanu & D.J. Lindner. 2001. Inositol hexakisphosphate kinase 2 mediates growth suppressive and apoptotic effects of interferon-β in ovarian carcinoma. J. Biol. Chem. 276: 24965-24970.
54. Colditz, G.A., K.Y. Wolin & S. Gehlert. 2012. Applying what we know to accelerate cancer prevention. Sci. Transl. Med. 4: 127, doi: 10.1126/scitranslmed.3003218.
55. Doll, R. & R. Peto. 1981. The Causes of Cancer: Quantitative Estimates of Avoidable Risks of Cancer in United States Today. Oxford University Press. New York.
56. Wiseman, M. 2008. The second World Cancer Research Fund/American Institute for Cancer Research expert report. Food, nutrition, physical activity, and the prevention of cancer: a global perspective. Proc. Nutr. Soc. 67: 253-256.
57. Thompson, R. 2010. Preventing cancer: the role of food, nutrition, and physical activity. J. Fam. Health Care 20: 100-102.
58. Griggs, J.J., M.E. Sorbero & G.H. Lyman. 2005. Undertreatment of obese women receiving breast cancer chemotherapy. Arch. Intern. Med. 165: 1267-1273.
59. Wong, J.R., Z. Gao, S. Merrick, et al. 2009. Potential for higher treatment failure in obese patients: correlation of elevated body mass index and increased daily prostate deviations from the radiation beam isocenters in an analysis of 1, 465 computed tomographic images. Int. J. Radiat. Oncol. Biol. Phys. 75: 49-55.
60. Healy, L.A., A.M. Ryan, E. Sutton, et al. 2010. Impact of obesity on surgical and oncologic outcomes in the management of colorectal cancer. Int. J. Colorectal Dis. 25: 1293-1299.
61. Al-Refaie, W.B., H.M. Parsons, W.G. Henderson, et al. 2010. Body mass index and major cancer surgery outcomes: lack of association or need for alternative measurements of obesity Ann. Surg. Oncol. 17: 2264-2273.